@OncLive

Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.

 New Jersey, USA
onclive.com
Joined May 2009
  • Tweets121K
  • Following2K
  • Followers50.5K
24.5KMedia
It's somehow time for our last day of ✨LIVE✨ filmings at this year's @myESMO #ESMO26 Congress! 🎥 Are you in Madrid and presenting key data? Reach out to our team to set up an exclusive interview. We would love to speak with you! Follow along for the latest updates from the meeting and to see who we have in the chair today 👉: onclive.com/conference/esmo-…
1
3
5
486
OncLive.com retweeted
Hope Rugo@hoperugoOct 26
#ESMO26 nice summary by Antonio Llombart on CNS studies in mHER2 positive disease! Congrats to all. @OncoAlert
19
31
1,237
OncLive.com retweeted
Stephen V Liu, MD
@StephenVLiu21h
#ESMO26 The brilliant Dr. @marinagarassino with biomarker analysis from the phase III KEYNOTE 671 study of perioperative pembrolizumab for resectable NSCLC showing association of T-cell inflamed gene expression profile and TMB with efficacy. Benefit across subgroups; inflamed profile associated with better prognosis. #ESMOAmbassadors
13
25
1,653
OncLive.com retweeted
Sara Tolaney@stolaney1Oct 26
DESTINY-Breast09 CNS Analysis Assessment of pts with BICR-assessed brain mets (treated and asymptomatic or clinically inactive) n=61 Deeper systemic and CNS response, and higher iORR @OncoAlert #ESMO26
1
13
19
958
Congrats @drchoueiri @danafarber on a very well delivered presentation, encompassing a lot of the data we need to understand the "why" (i.e., toxicity burden, discontinuation, etc.). I personally think the next phase of 1L drug development with #kidneycancer (if we are to proceed with triplets) will have to involve agents with a wide therapeutic index so administration of Drug 3 does not cause delays/interruptions w Drug 1 + 2. In this regard, hopeful for @SWOG #S2419 (#BIOFRONT) led by @PBarataMD, investigating IO-backbone +/- #MO03 (a live bacterial product). #ESMO26 @oncoalert @brian_rini @tompowles1
Toni Choueiri, MD
@DrChoueiriOct 25
More is not always better in 1L RCC! Presenting LITESPARK-012 Ph.III: adding belzutifan or CTLA-4 blockade to Pembro/Len failed to improve PFS or OS. PFS HR 1.08/1.07; OS HR 1.04/1.12. ORR 69%/69% vs 76% SOC. #ESMO26 #RCC @myESMO @OncoAlert
1
13
34
1,543
More is not always better in 1L RCC! Presenting LITESPARK-012 Ph.III: adding belzutifan or CTLA-4 blockade to Pembro/Len failed to improve PFS or OS. PFS HR 1.08/1.07; OS HR 1.04/1.12. ORR 69%/69% vs 76% SOC. #ESMO26 #RCC @myESMO @OncoAlert
2
28
1
64
4,114
Exciting data at #ESMO26 by Dr. Liangyou Gu on novel imagining for kidney CA 🩻 💫 novel CAIX-targeted [68Ga] PET provides accurate primary ccRCC identification and superior detection of lymph node, lung & bone mets over regular 2-[18F]FDG PET, esp in small-volume lesions
1
11
21
913
OncLive.com retweeted
Tom Powles
@tompowles116h
The MOIO randomised phase 3 non-inferiority trial (n=340) explored early discontinuation of ICI therapy be SOC in advanced patients responding to therapy. It had many flaws (mixed tumors and treatments, small size, early discontinuation etc). Also, due to the statistics, it’s not possible to say whether non-inferiority was achieved (OS HR 1.89 [95%Cl: 1.03,3.48]). Despite these problems it highlights a concern around early discontinuation, which should be taken seriously. Tumour specific trials are needed, but I’m not sure it will be easy to randomize patients . #ESMO26 @OncoAlert @myESMO @Annals_Oncology
1
25
40
1,974
OncLive.com retweeted
Angela Lamarca@DrAngelaLamarca21h
Upper GI #RapidOral session at @myESMO #ESMO26 iKRAS G12D PDAC HRS-4642 + chemo + PDL1 🤩Perioperative🤩 ✅ORR - above 60% 🤔R0 - 100% 😊Reports pathological response 💪Good signal, let’s pursue #ESMOAmbassadors
10
1
22
2,604
OncLive.com retweeted
Sara Coca Membribes@scocmem23h
A valuable session on mentorship and career development at #ESMO26 @myESMO Thanks to @FerMosele @AndresC27622123 @LoiSher for sharing their insights @OncoAlert
8
21
937
OncLive.com retweeted
Stephen V Liu, MD
@StephenVLiu21h
Important longer follow up from DeLLphi-304 (2L tarlatamab vs SCLC) presented by Dr. @charlesrudin at #ESMO26 simultaneously published @Annals_Oncology. Median PFS 4.2 vs 3.2m, mOS 13.6 vs 8.4m, 2y OS 30% vs 15%, RR 35% vs 20% #ESMOAmbassadors annalsofoncology.org/article…

Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based...

In the DeLLphi-304 trial, at a median follow-up of <12 months, tarlatamab significantly improved overall survival (OS), progression-free survival (PFS), and patient-reported outcomes (PROs), and...

annalsofoncology.org
1
10
35
1,936
OncLive.com retweeted
Stephen V Liu, MD
@StephenVLiu20h
#ESMO26 Dr. Mary O'Brien presents final analysis of phase III PEARLS/KEYNOTE-091 trial: adjuvant pembrolizumab for resected NSCLC with 87m f/u. In pts who received adjuvant chemo, DFS 58.7 vs 39.1m (HR 0.80) and no difference in survival: OS HR 0.91 with 6y DFS 69% vs 65%. In that group, improved lung cancer specific survival (HR 0.69, 6y rate 82% vs 75%). #ESMOAmbassadors
1
15
25
2,331
OncLive.com retweeted
Sara Tolaney@stolaney1Oct 26
Beautiful presentation by @PTarantinoMD on paired pre/post biopsies on ADC Multifactorial resistance mechanisms for ADCs @OncoAlert #ESMO26
1
25
45
1,829
OncLive.com retweeted
Sara Tolaney@stolaney1Oct 26
SWITCH trial: ADC switching 25% HR+ 75% TNBC ORR: 0-8.3%, PFS 1.4-3.0 mo @OncoAlert #ESMO26
23
44
2,075
Beautiful discussion of #MOIO at #ESMO26 - a masterclass in distilling a high impact clinical trial into clinically relevant take home messages! Bravo @DrJNaidoo! @OncoAlert
2
12
1
36
1,736
Brilliant discussion by @ZaydTippu, tying together #ESMO26 abstracts from @AlbigesL, @VincentWenxinXu & @DrDanielHeng. Not easy to weave between abstracts pertaining to PD-L1 assessment in #CARE1, #KIM1 in #COSMIC313 & #HRQOL in #LITESPARK11, but he pulls together a very cohesive story. Definitely worth a watch! @OncoAlert
13
28
1,242
Replying to @RobinL_Jones
@RobinL_Jones presented the #Phase3 #Peak crossover: Bezuclastinib + sunitinib combination following sunitinib monotherapy in patients with GIST. Improved ORR (20.3 vs. 29.7%) and duration of response (5.7 vs 7.4m) in pts who were crossed over from #sunitinib to #bez+sunitinib. #GIST #sarcoma #ESMO26 @myesmo @ctosociety #ESMOAmbassadors
7
16
508
#SebastianBauer presented on behalf of investigators of #StrateGIST1 study on role #velzatinib of #molecularresponse in KIT ctDNA in response - confirming rapid disease control associated with clinical response. Exciting times in novel therapeutic options for GISTs! #Sarcoma #drugdevelopment @ctosociety #ESMO26 #ESMOAmbassadors @myESMO
1
4
11
495
OncLive.com retweeted
Sara Tolaney@stolaney1Oct 26
OptiTROP-Breast01 Sac-TMT vs chemo in mTNBC (≥2chemo/≥1 in MBC) OS: 14.7 vs 9.9 mo, HR 0.60, p=0.0004 @OncoAlert #ESMO26
2
23
1
46
2,813
OncLive.com retweeted
Shilpa Gupta
@shilpaoncOct 26
What a productive couple of days at #ESMO26! From a packed Presidential Symposium to catching up with friends and colleagues from around the 🌎, it's these meaningful connections that turn conversations into collaborations. @myESMO @OncoAlert @Uromigos @weoncologists @uromigosjapan @LosUromigos @brian_rini @tompowles1 @DrChoueiri @IBCG_BladderCA @CParkMD
2
10
47
953
Kudos to Dr. Yelena Janjigian @YJanjigianMD for the great progress her ongoing research has brought to the GI Oncology field, she is an esteemed colleague and outstanding collaborator. And congratulations for a fantastic #ESMO26 meeting as Scientific Committee Co-Chair, and the groundbreaking phase 3 data on Claudin 18.2 ADC!! @MSKCancerCenter certainly has the best representation at @myESMO
1
7
15
702
Load more